Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy.

摘要: Capturing the patient experience during treatment is important to both regulatory authorities and patients starting treatment. We identified symptoms side effects experienced by with advanced non-small-cell lung cancer osimertinib treatment, understand expectations, satisfaction, level of difficulty coping Qualitative interviews (approximately 4–6 weeks after initiation again approximately 4 months treatment) were conducted phase I/II AURA clinical trial osimertinib, a tyrosine kinase inhibitor epidermal growth factor receptor-sensitizing T790M resistance mutations. During first interview (23 patients), most commonly reported symptoms/side coughing, itching, tiredness (each 56.5% rash (43.5%). second (21 compared interview, shortness breath diarrhea more (57.1 38.1%, respectively; increased from 34.8%); remained predominant (42.9%); itching (38.1%), coughing (14.3%) fewer patients. At interviews, frequently also those often rated for bothersomeness severity, generally received mean scores in low-to-moderate range. However, several rarely expressed (e.g., abdominal pain, frequent day time urination) high ratings. highly satisfied had low These data enhance our understanding patients’ experiences effects, which could increase accuracy benefit–risk assessment, guide management adverse events, improve information given receiving drug.